Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | BTK | Q06187 | 3/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | TET3 | O43151 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.31 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.31 |
| ▸ | TET1 | Q8NFU7 | 2/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.31 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.31 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375288 | 0.85 | HRH3 (0.41) | JAK3HRH3KMT2ACYP2D6 | |
| SCHEMBL24854333 | 0.84 | HRH3 (0.46) | JAK3HRH3BTKTET3KMT2A | |
| SCHEMBL16127680 | 0.79 | JAK3 (0.42) | JAK3BTKKRASTET3KMT2A | |
| SCHEMBL12026664 | 0.76 | SMN1; SMN2 (0.42) | HRH3CYP2D6 | |
| SCHEMBL3469565 | 0.76 | HRH3 (0.44) | HRH3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL15474352 | 0.75 | BTK (0.41) | JAK3BTKKRASTEAD1KCNH2 | |
| SCHEMBL25870417 | 0.75 | KMT2A (0.43) | HRH3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL23682421 | 0.75 | TET3 (0.33) | JAK3BTKKRASTET3KMT2A | |
| SCHEMBL24092956 | 0.75 | TET3 (0.33) | JAK3BTKKRASTET3KMT2A | |
| SCHEMBL25557231 | 0.75 | CHRNB2 (0.38) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | JAK3 105/4885HRH3 3109/4885BTK 2/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | JAK3 3209/4885HRH3 2555/4885BTK 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.